Sex and Gender-based Analysis of the Effectiveness of Advanced Therapies in Psoriatic Arthritis

Study investigators will perform a prospective, multi-center, international cohort study involving approximately 30 sites that specialize in care of patients with PsA. 540 patients with a rheumatologist-confirmed diagnosis of PsA who are initiating advanced therapy for peripheral musculoskeletal manifestations of PsA will be enrolled. The study will include 2 in-person physician visits. Visit 1 (baseline) will take place prior to drug initiation (up to 3 months prior). Visit 2 (follow-up) will occur 3-6 months following drug initiation. In addition, study sites will be asked to report persistence status on the study drug at 1 year.

Inclusion criteria

• Rheumatologist confirmed diagnosis of PsA according to CASPAR criteria
• Age ≥18 years
• Active PsA with any of the following manifestations detected on physical examination: peripheral arthritis, dactylitis, and enthesitis. The patient may have axial involvement in addition to the peripheral manifestations of PsA
• Plan to start treatment with advanced therapies for peripheral musculoskeletal manifestations of PsA

Exclusion criteria

• Unable to read or write
• Unable to sign informed consent
• Cannot return for a follow up visit
• The drug is given for another indication and not for active PsA (e.g. psoriasis, IBD)
• Pregnant women